{"id":"NCT03579459","sponsor":"Pfizer","briefTitle":"Evaluation Of Clostridium Difficile Vaccine Lot Consistency In Healthy Adults 65 To 85 Years Of Age","officialTitle":"A PHASE 3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE LOT CONSISTENCY, SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN HEALTHY ADULTS 65 TO 85 YEARS OF AGE","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-07-31","primaryCompletion":"2019-08-06","completion":"2019-08-06","firstPosted":"2018-07-06","resultsPosted":"2023-01-19","lastUpdate":"2023-01-19"},"enrollment":1317,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Clostridium Difficile Associated Disease"],"interventions":[{"type":"BIOLOGICAL","name":"Clostridium difficile vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"placebo","otherNames":["0.9% sodium chloride"]}],"arms":[{"label":"Clostridium difficile vaccine Lot 1","type":"ACTIVE_COMPARATOR"},{"label":"Clostridium difficile vaccine Lot 2","type":"ACTIVE_COMPARATOR"},{"label":"Clostridium difficile vaccine Lot 3","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study will investigate a Clostridium difficile vaccine in healthy adults 65 to 85 years of age, who will each receive 3 doses of vaccine. The study will assess the lot consistency, safety, and tolerability of the vaccine, and also look at the subjects' immune response to the vaccine.","primaryOutcome":{"measure":"Geometric Mean Concentrations (GMCs) of Clostridium Difficile Toxin A and Toxin B Specific Neutralizing Antibodies at Month 7","timeFrame":"At Month 7","effectByArm":[{"arm":"Clostridium Difficile Vaccine: Lot 1","deltaMin":878.8,"sd":null},{"arm":"Clostridium Difficile Vaccine: Lot 2","deltaMin":873,"sd":null},{"arm":"Clostridium Difficile Vaccine: Lot 3","deltaMin":872.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG001 vs OG002","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG001 vs OG002","p":null}]},"eligibility":{"minAge":"65 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":14},"locations":{"siteCount":24,"countries":["United States"]},"refs":{"pmids":["37977942"],"seeAlso":["https://pmiform.com/clinical-trial-info-request?StudyID=B5091008"]},"adverseEventsSummary":{"seriousAny":{"events":41,"n":983},"commonTop":["Fatigue (FATIGUE)","Injection site pain (PAIN)","Headache (HEADACHE)","Myalgia (MUSCLE PAIN)","Arthralgia (JOINT PAIN)"]}}